← Back to Clinical Trials
Recruiting NCT06305949

NCT06305949 Clinical Trial on the Safety and Efficacy of Optimized Transcranial Direct Current Stimulation for the Swallowing Function in Patients With Post-Stroke Dysphagia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06305949
Status Recruiting
Phase
Sponsor NEUROPHET
Condition Deglutition Disorders
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-04-22
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Optimized transcranial Direct Current StimulationSham transcranial Direct Current Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-04-22 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to evaluate whether the application of optimized transcranial direct current stimulation is more effective compared to sham stimulation for temporary improvement of swallowing function in patients with post-stroke dysphagia.

Eligibility Criteria

Inclusion Criteria: * men and women \>19 years old * patients with stroke confirmed by neuroimaging * first-time stroke patients * patients in subacute or chronic phases of stroke with 3 weeks or more after onset * stroke patients with confirmed dysphagia through Videofluoroscopic Swallowing Study (VFSS). Exclusion Criteria: * patients with recurrent stoke, traumatic brain injury, spine cord injury, and degenerative brain disease, such as Parkinson's disease, etc. * patients with deteriorated cognitive function unable to perform the clinical trial as instructed * patients with evidence of delirium, confusion, or other impairment of consciousness * patients with uncontrolled medical disease or surgical conditions * patients ineligible for Transcranial direct current stimulation (due to scalp condition, metallic material at the electrode attachment area, presence of a pacemaker or cochlear implant) * patients with previous experience within the last year using a stimulation device similar to the one use in this clinical trial or who have participated in related clinical trials * patients with severe neurologic disorder with concomitant major psychiatric disorder such as major depressive disorder and dementia * patients with history of uncontrolled epilepsy within 6 months * patients with medical contraindications for neuroimaging test, such as MRI; * patients who are taken contraindicated medications or require medication changes during the trial period that could influence cognitive/motor function changes via brain activation changes * patients who are pregnant, breastfeeding, or planning pregnancy during the trial period * patients considered medically ineligible for participation in the present trial beyond the criteria listened above.

Contact & Investigator

Central Contact

TaeYeong Kim

✉ ty.kim@neurophet.com

📞 827051678882

Frequently Asked Questions

Who can join the NCT06305949 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Deglutition Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06305949 currently recruiting?

Yes, NCT06305949 is actively recruiting participants. Contact the research team at ty.kim@neurophet.com for enrollment information.

Where is the NCT06305949 trial being conducted?

This trial is being conducted at Bucheon-si, South Korea.

Who is sponsoring the NCT06305949 clinical trial?

NCT06305949 is sponsored by NEUROPHET. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology